Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

CDD-3290

😃Good
Catalog No. T89314

CDD-3290 represents a highly specialized small molecule inhibitor specifically engineered to target the catalytic activity of Prostate-Specific Antigen (PSA/KLK3) with exceptional inhibitory potency. It effectively facilitates the measurable blockade of PSA-mediated proteolytic cleavage across various preclinical experimental models to evaluate the disruption of the tumor microenvironment during strictly monitored laboratory observation periods and enzyme kinetic assays to ensure high experimental sensitivity.

CDD-3290

CDD-3290

😃Good
Purity: 99.13%
Catalog No. T89314
CDD-3290 represents a highly specialized small molecule inhibitor specifically engineered to target the catalytic activity of Prostate-Specific Antigen (PSA/KLK3) with exceptional inhibitory potency. It effectively facilitates the measurable blockade of PSA-mediated proteolytic cleavage across various preclinical experimental models to evaluate the disruption of the tumor microenvironment during strictly monitored laboratory observation periods and enzyme kinetic assays to ensure high experimental sensitivity.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$185-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.13%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity
Description
CDD-3290 represents a highly specialized small molecule inhibitor specifically engineered to target the catalytic activity of Prostate-Specific Antigen (PSA/KLK3) with exceptional inhibitory potency. It effectively facilitates the measurable blockade of PSA-mediated proteolytic cleavage across various preclinical experimental models to evaluate the disruption of the tumor microenvironment during strictly monitored laboratory observation periods and enzyme kinetic assays to ensure high experimental sensitivity.
In vitro
In biochemical enzyme assays using purified human PSA protein, CDD-3290 inhibited protease activity with IC50 values in the low micromolar range and demonstrated selectivity over other kallikreins [1].
In vivo
In mouse models of prostate cancer, local or systemic administration of CDD-3290 significantly inhibited PSA-mediated proteolytic activity and reduced tumor-associated growth factor activation [1].
Chemical Properties
Molecular Weight334.33
FormulaC17H14N6O2
SmilesCOC1=NC=C(C=C1)C2=NN(C(=C2)N)C(=O)C3=CC4=C(C=C3)N=CN4
Storage & Solubility Information
Storagestore at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy CDD-3290 | purchase CDD-3290 | CDD-3290 cost | order CDD-3290 | CDD-3290 chemical structure | CDD-3290 in vivo | CDD-3290 in vitro | CDD-3290 formula | CDD-3290 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.